CN113330008A - 酰胺类化合物制备方法及其在医药领域的应用 - Google Patents

酰胺类化合物制备方法及其在医药领域的应用 Download PDF

Info

Publication number
CN113330008A
CN113330008A CN202080009085.3A CN202080009085A CN113330008A CN 113330008 A CN113330008 A CN 113330008A CN 202080009085 A CN202080009085 A CN 202080009085A CN 113330008 A CN113330008 A CN 113330008A
Authority
CN
China
Prior art keywords
methyl
pyran
ethyl
amino
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080009085.3A
Other languages
English (en)
Other versions
CN113330008B (zh
Inventor
李云飞
许忻
张瑱
张立明
武琦梅
夏小二
蒋青云
王龙刚
郭凤英
于浩
周晓波
刘磊
张小娟
王艺瑾
葛建
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhejiang Huahai Pharmaceutical Co Ltd
Shanghai Synergy Pharmaceutical Sciences Co Ltd
Original Assignee
Zhejiang Huahai Pharmaceutical Co Ltd
Shanghai Synergy Pharmaceutical Sciences Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhejiang Huahai Pharmaceutical Co Ltd, Shanghai Synergy Pharmaceutical Sciences Co Ltd filed Critical Zhejiang Huahai Pharmaceutical Co Ltd
Publication of CN113330008A publication Critical patent/CN113330008A/zh
Application granted granted Critical
Publication of CN113330008B publication Critical patent/CN113330008B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

提供一种酰胺类化合物制备方法及其在医药领域的应用。具体地，提供了一种酰胺类小分子化合物，该类化合物为Zeste基因增强子同源物2(EZH2)的抑制剂，可用于预防和/或治疗EZH2介导的相关疾病，包括肿瘤、骨髓增生性疾病或自身免疫性疾病。

Description

PCT国内申请，说明书已公开。

Claims (14)

  1. PCT国内申请，权利要求书已公开。
CN202080009085.3A 2019-03-25 2020-03-24 酰胺类化合物制备方法及其在医药领域的应用 Active CN113330008B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2019102282448 2019-03-25
CN201910228244 2019-03-25
CN201910687575 2019-07-29
CN2019106875758 2019-07-29
PCT/CN2020/080874 WO2020192652A1 (zh) 2019-03-25 2020-03-24 酰胺类化合物制备方法及其在医药领域的应用

Publications (2)

Publication Number Publication Date
CN113330008A true CN113330008A (zh) 2021-08-31
CN113330008B CN113330008B (zh) 2024-05-07

Family

ID=72608495

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202080009085.3A Active CN113330008B (zh) 2019-03-25 2020-03-24 酰胺类化合物制备方法及其在医药领域的应用
CN202080018781.0A Pending CN113631541A (zh) 2019-03-25 2020-03-24 酰胺类化合物制备方法及其在医药领域的应用

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202080018781.0A Pending CN113631541A (zh) 2019-03-25 2020-03-24 酰胺类化合物制备方法及其在医药领域的应用

Country Status (5)

Country Link
US (2) US20220098178A1 (zh)
EP (2) EP3950676A4 (zh)
JP (2) JP7395807B2 (zh)
CN (2) CN113330008B (zh)
WO (2) WO2020192652A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114886892A (zh) * 2022-05-07 2022-08-12 四川大学 氧化吲哚螺双环[2,2,1]庚烷类化合物在制备治疗胃癌药物中的应用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220098178A1 (en) * 2019-03-25 2022-03-31 Shanghai Synergy Pharmaceutical Sciences Co., Ltd. Preparation Method for Amide Compound and Application Thereof in Field of Medicine
CN115197202B (zh) * 2022-07-15 2024-01-26 四川大学 一种ezh2共价抑制剂及其制备方法和应用
CN117736436B (zh) * 2023-12-27 2024-05-24 南京审计大学 一种含硼聚合物及其制备方法和应用

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013173441A2 (en) * 2012-05-16 2013-11-21 Glaxosmithkline Llc Enhancer of zeste homolog 2 inhibitors
CN104080769A (zh) * 2011-04-13 2014-10-01 Epizyme股份有限公司 芳基或杂芳基取代苯化合物
WO2014172044A1 (en) * 2013-03-15 2014-10-23 Epizyme, Inc. Substituted benzene compounds
WO2015010049A1 (en) * 2013-07-19 2015-01-22 Epizyme, Inc. Substituted benzene compounds
WO2015110999A1 (en) * 2014-01-24 2015-07-30 Piramal Enterprises Limited Ezh2 inhibitors and uses thereof
US20170217941A1 (en) * 2014-06-25 2017-08-03 Epizyme, Inc. Substituted benzene and 6,5-fused bicyclic heteroaryl compounds
WO2017139404A1 (en) * 2016-02-08 2017-08-17 Epizyme, Inc. Methods of treating cancer

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2108641A1 (en) 2008-04-11 2009-10-14 Laboratorios Almirall, S.A. New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors
WO2012005805A1 (en) 2010-05-07 2012-01-12 Glaxosmithkline Llc Azaindazoles
SG180031A1 (en) 2010-10-15 2012-05-30 Agency Science Tech & Res Combination treatment of cancer
EP2681216B1 (en) 2011-02-28 2017-09-27 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
TW201733984A (zh) 2011-04-13 2017-10-01 雅酶股份有限公司 經取代之苯化合物
KR20200062386A (ko) * 2012-04-13 2020-06-03 에피자임, 인코포레이티드 암 치료용 병용 요법
CA2884848C (en) 2012-09-28 2017-08-22 Pfizer Inc. Benzamide and heterobenzamide compounds
CA2905070A1 (en) * 2013-03-14 2014-09-25 Genentech, Inc. Methods of treating cancer and preventing cancer drug resistance
EP3119390A4 (en) 2014-03-21 2017-09-20 Glaxosmithkline Intellectual Property (No. 2) Limited Methods of treating cancer
WO2016102493A1 (en) 2014-12-22 2016-06-30 Bayer Pharma Aktiengesellschaft Imidazopyridine ezh2 inhibitors
US10759787B2 (en) 2015-11-19 2020-09-01 Jiangsu Hengrui Medicine Co., Ltd. Benzofuran derivative, preparation method thereof and use thereof in medicine
AU2017323112B2 (en) 2016-09-07 2020-11-26 Haihe Biopharma Co., Ltd. Pyrido five-element aromatic ring compound, preparation method therefor and use thereof
CN108314677B (zh) * 2017-01-17 2020-06-30 安徽中科拓苒药物科学研究有限公司 一种ezh2抑制剂及其用途
CN110191879A (zh) 2017-01-25 2019-08-30 恩瑞生物医药科技（上海）有限公司 一种组蛋白甲基转移酶ezh2抑制剂、其制备方法及其医药用途
US20220098178A1 (en) 2019-03-25 2022-03-31 Shanghai Synergy Pharmaceutical Sciences Co., Ltd. Preparation Method for Amide Compound and Application Thereof in Field of Medicine

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104080769A (zh) * 2011-04-13 2014-10-01 Epizyme股份有限公司 芳基或杂芳基取代苯化合物
WO2013173441A2 (en) * 2012-05-16 2013-11-21 Glaxosmithkline Llc Enhancer of zeste homolog 2 inhibitors
WO2014172044A1 (en) * 2013-03-15 2014-10-23 Epizyme, Inc. Substituted benzene compounds
WO2015010049A1 (en) * 2013-07-19 2015-01-22 Epizyme, Inc. Substituted benzene compounds
WO2015110999A1 (en) * 2014-01-24 2015-07-30 Piramal Enterprises Limited Ezh2 inhibitors and uses thereof
US20170217941A1 (en) * 2014-06-25 2017-08-03 Epizyme, Inc. Substituted benzene and 6,5-fused bicyclic heteroaryl compounds
WO2017139404A1 (en) * 2016-02-08 2017-08-17 Epizyme, Inc. Methods of treating cancer

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114886892A (zh) * 2022-05-07 2022-08-12 四川大学 氧化吲哚螺双环[2,2,1]庚烷类化合物在制备治疗胃癌药物中的应用
CN114886892B (zh) * 2022-05-07 2023-09-12 四川大学 氧化吲哚螺双环[2,2,1]庚烷类化合物在制备治疗胃癌药物中的应用

Also Published As

Publication number Publication date
JP2022528337A (ja) 2022-06-10
EP3950682A1 (en) 2022-02-09
WO2020192650A1 (zh) 2020-10-01
US20220024941A1 (en) 2022-01-27
EP3950676A1 (en) 2022-02-09
WO2020192652A1 (zh) 2020-10-01
CN113631541A (zh) 2021-11-09
US20220098178A1 (en) 2022-03-31
JP2022528042A (ja) 2022-06-08
JP7396369B2 (ja) 2023-12-12
CN113330008B (zh) 2024-05-07
EP3950682A4 (en) 2022-08-03
EP3950676A4 (en) 2022-08-10
JP7395807B2 (ja) 2023-12-12

Similar Documents

Publication Publication Date Title
CN111377917B (zh) 杂环类化合物、中间体、其制备方法及应用
CN113999226B (zh) 作为kras抑制剂的杂环化合物的制备及其应用方法
CN113330008A (zh) 酰胺类化合物制备方法及其在医药领域的应用
CN112110918A (zh) 螺环取代的嘧啶并环类化合物，其制法与医药上的用途
JP2019104734A (ja) 治療活性化合物及びその使用
KR20160132041A (ko) Trpm8 길항제로 사용되는 아자스피로 유도체
WO2022135470A1 (zh) 作为kras抑制剂的杂环化合物的制备及其应用方法
CN112566905A (zh) 取代的苯基丙烯基吡啶类衍生物，其制法与医药上的用途
CN114728962A (zh) 血浆激肽释放酶抑制剂及其用途
WO2021093795A1 (zh) 一种rock抑制剂及其制备方法和用途
CN105524068A (zh) 氮杂双环衍生物、其制法与医药上的用途
CN110494431B (zh) 氮杂环类衍生物、其制备方法及其医药用途
CN111343988A (zh) 作为ehmt2抑制剂的胺取代的杂环化合物及其衍生物
JP2022535577A (ja) 癌を処置するためのｐｒｃ２阻害剤としてのイミダゾ［１，２－ｃ］ピリミジン誘導体
CN115667226A (zh) 作为egfr抑制剂的三环化合物
WO2018113694A1 (zh) 稠环基氮杂环丁基三唑类衍生物、其制备方法及其在医药上的应用
WO2022199662A1 (zh) 一种多环化合物及其应用
CN113544129A (zh) 三环类化合物制备方法及其在医药领域的应用
CN115960094A (zh) 一类芳香环取代的甲胺衍生物的制备及其用途
CN113264945B (zh) 一种螺环衍生物、其制备方法及其在医药上的应用
CN115515959A (zh) 用作tead结合剂的三环杂环
CN113880833A (zh) 联苯多环类衍生物抑制剂、其制备方法和应用
CN112839931A (zh) 1,2,3,4-四氢喹喔啉衍生物及其制备方法和应用
WO2023216753A1 (zh) 咪唑并哒嗪取代苯环类衍生物、制备方法、药物组合物及用途
WO2022122037A1 (zh) 一种二氢异喹啉酮衍生物及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB03 Change of inventor or designer information
CB03 Change of inventor or designer information

Inventor after: Xu Xin

Inventor after: Zhang Xiaojuan

Inventor after: Sun Kang

Inventor after: Zhou Xiaobo

Inventor after: Zang Chengxu

Inventor after: Wang Yijin

Inventor after: Xia Xiaoer

Inventor after: Li Yunfei

Inventor after: Ge Jian

Inventor after: Chen Jia

Inventor after: Zhang Tian

Inventor after: Zhang Liming

Inventor after: Wu Qimei

Inventor after: Jiang Qingyun

Inventor after: Guo Fengying

Inventor after: Zhang Yuyun

Inventor after: Yu Hao

Inventor before: Li Yunfei

Inventor before: Yu Hao

Inventor before: Zhou Xiaobo

Inventor before: Liu Lei

Inventor before: Zhang Xiaojuan

Inventor before: Wang Yijin

Inventor before: Ge Jian

Inventor before: Xu Xin

Inventor before: Zhang Tian

Inventor before: Zhang Liming

Inventor before: Wu Qimei

Inventor before: Xia Xiaoer

Inventor before: Jiang Qingyun

Inventor before: Wang Longgang

Inventor before: Guo Fengying

GR01 Patent grant
GR01 Patent grant